Vulvar lichen sclerosus treatments: the complete clinical landscape
VLS treatment has advanced significantly in the last decade. In this guide, I present the complete landscape of available options—from the first line established by international guidelines to alternatives for cases with insufficient response—with the information you need to make informed clinical decisions.
What VLS treatment aims to achieve
Vulvar lichen sclerosus treatment has two distinct clinical objectives that should be separated from the outset:
Symptomatic control
reduce itching, burning, pain, and dyspareunia that affect the patient's quality of life. This objective is achieved with relative efficacy using first-line treatments.
Halting tissue progression
limit the accumulated structural damage—atrophy, fibrosis, anatomical changes—that VLS produces progressively. This objective is more difficult to achieve with conventional treatments and is the area where regenerative medicine provides differential value.
No currently available treatment eliminates the underlying autoimmune predisposition.
Discontinuing maintenance treatment usually leads to relapse.
First line: ultrapotent topical corticosteroids
Ultrapotent topical corticosteroids—primarily clobetasol propionate 0.05%—are the first-line treatment for VLS according to the BAD 2018 and EADV 2024 international guidelines. This recommendation is supported by decades of clinical use and by evidence that, although not of the highest methodological levels, is consistent and widely endorsed.
Clobetasol works by reducing the local inflammatory response: it decreases immune system activity in vulvar tissue, which relieves symptoms and slows lesion progression. It does not repair already damaged tissue, but it is very effective for symptomatic control in most patients.
The regimen matters as much as the drug. The usual initial regimen is one application daily for 4–12 weeks, followed by a gradual taper to the maintenance regimen—which in many cases is one application weekly indefinitely. Discontinuation of maintenance treatment often leads to relapse.
Alternatives when corticosteroids are not sufficient
Topical tacrolimus (calcineurin inhibitors)
Tacrolimus 0.1% ointment is the most established alternative to clobetasol. It works through a different mechanism—calcineurin inhibition, which blocks T-lymphocyte activation—and can be especially useful in areas where prolonged corticosteroid use is problematic, such as the perianal area or in patients with significant atrophy from previous steroid use. It is not the first line according to current guidelines, but it is supported by published evidence and is a validated option in clinical practice. Its use is approved for atopic dermatitis; in VLS it is used in routine clinical practice although it does not have specific approved indication in the product information for this disease. This does not mean that VLS is hereditary in the classical sense—it is not transmitted directly from mother to daughter—but rather that there is a genetic predisposition that, combined with other factors, can lead to disease development.
Non-hormonal and supportive treatments
Other measures complement pharmacological treatment: specific vulvar moisturizers, adapted hygiene measures, and irritant avoidance. These are especially important in long-term maintenance. They do not replace corticosteroid treatment, but they reduce symptomatic burden and improve quality of life.
Regenerative medicine: when corticosteroids are not sufficient
For a specific patient profile—insufficient response to corticosteroids, significant progressive tissue damage, or high symptomatic burden despite conventional treatment—regenerative medicine offers a different approach: acting on the affected tissue to promote its regeneration, not just controlling inflammation from the outside.
The most commonly used regenerative techniques in the VLS context include platelet-rich plasma (PRP) and adipose tissue fractions—nanofat and stromal vascular fraction (SVF). Their mechanism of action—anti-inflammatory and immunomodulatory effect on vulvar tissue—makes them biologically coherent with VLS pathophysiology.
The Liquenia® Treatment is the protocol we have developed specifically for VLS, combining nanofat and SVF in a standardized procedure with published clinical evidence. It is one option, not the only one—and its indication depends on each patient’s individual clinical situation.
Reconstructive surgery for sequelae
When VLS has produced established anatomical changes—advanced labial fusion, clitoral phimosis, severe introital narrowing—medical treatment can control inflammation but cannot reverse those structural changes. In these cases, vulvar reconstructive surgery may be indicated.
Surgery in the VLS context requires a specialist with specific experience in reconstructive vulvar surgery, and must be carefully planned in combination with continued medical treatment—operating without control of active disease increases the risk of scar recurrence.
For reconstructive surgery for VLS sequelae, we collaborate with the cirugiavaginal.info team, specialized in this type of intervention.
How to choose the appropriate treatment
There is no single treatment valid for all patients with VLS. The choice depends on multiple factors that can only be evaluated in consultation:
> Disease stage—the response to corticosteroids is different in early stages than in advanced stages with established fibrosis
> Response to previous treatments—if corticosteroids have controlled the disease well, there is no reason to change; if the response has been insufficient, alternatives must be explored
> Degree of tissue damage—the presence of significant anatomical changes points toward options that act on the tissue, not just on inflammation
> Patient preferences and circumstances—treatment tolerance, availability for follow-up, logistical factors
In our practice, treatment choice is always the result of an individual assessment—not a fixed protocol.